Home › Companies › AQUESTIVE THERAPEUTICS INC. › 2024-2025

AQUESTIVE THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and AQUESTIVE THERAPEUTICS INC.’s Form 8-K, filed 2025-06-11 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Reported items
105Asset managers
469Fund votes
2025-06-11Meeting date

Proxy season: 2024-2025 2025-2026

Explore AQUESTIVE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by AQUESTIVE THERAPEUTICS INC.

These tallies are AQUESTIVE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-11 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AQUESTIVE THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-11
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Daniel Barber	36,060,882	--	3,546,668	--	29,848,112	Outcome not stated
(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.	32,454,278	6,694,084	459,188	--	29,848,112	Majority: yes
(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 was ratified.	66,530,646	1,166,766	1,758,250	--	--	Majority: yes

Source: AQUESTIVE THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-11 — read the filing on EDGAR.

How asset managers voted at the AQUESTIVE THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 105 asset managers that disclosed a AQUESTIVE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AQUESTIVE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST 17%

FOR: 32,454,278AGAINST: 6,694,084

AQUESTIVE THERAPEUTICS INC.’s own tally for this item (“(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.”): 32,454,278 for, 6,694,084 against, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,327,928 outstanding shares: 33% for, 7% against (39% of the company cast a for/against vote).

The 102 asset managers below cast 90% of the shares they voted on this item FOR (16,672,057 for, 1,775,655 against).

FOR 90%10%

FOR: 16,672,057 (90.4%)AGAINST: 1,775,655 (9.6%)

Largest asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at AQUESTIVE THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
BlackRock	4,575,897	8,082	For
Vanguard	3,917,288	1,770	For
PERCEPTIVE ADVISORS LLC	2,949,266	0	For
Janney Montgomery Scott LLC	1,064,760	0	For
Blue Owl Capital Holdings LP	920,000	0	For
State Street	662,870	4,578	For
Charles Schwab	421,363	0	For
Woodline Partners LP	401,493	0	For
Northern Trust	0	400,697	Against
STIFEL NICOLAUS & CO INC \MO\	0	363,687	Against
Latash Investments, LLC	243,134	0	For
Stonepine Capital Management, LLC	200,000	0	For
Equitable	103,991	55,290	For
DE Shaw	0	158,668	Against
Wellington	149,536	0	For
DAFNA Capital Management LLC	142,000	0	For
MELLON INVESTMENTS Corp	131,564	0	For
Citadel	127,027	0	For
Two Sigma	0	104,782	Against
Russell Investments	100,190	0	For
Goldman Sachs	0	96,153	Against
GEODE CAPITAL MANAGEMENT, LLC	91,805	0	For
Fidelity	90,124	0	For
AQR	0	66,138	Against
Beacon Pointe Advisors, LLC	60,000	0	For

Showing the 25 largest of 102 asset managers. See all 102 in the interactive database.

2. To elect Daniel Barber and Timothy E. Morris as Class I members of the Board of Directors, each to serve for a three-year term until the Company's 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified: Daniel Barber

DIRECTOR ELECTIONSOutcome not stated

Combines 3 wordings of this item as funds reported it.

— Outcome not stated · no against or withheld count reported

AQUESTIVE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Daniel Barber”): 36,060,882 for; no against or withheld count reported, per its Form 8-K filed 2025-06-11 (Item 5.07).

The 33 asset managers below cast 100% of the shares they voted on this item FOR (7,070,111 for, 0 against).

FOR 98%

FOR: 7,070,111 (98.1%)ABSTAIN: 137,379 (1.9%)

Largest asset managers voting on “To elect Daniel Barber and Timothy E. Morris as Class I members of the Board of Directors, each to serve for a” at AQUESTIVE THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,872,326	0	For
BlackRock	2,404,702	0	For
Charles Schwab	210,669	0	For
Equitable	159,281	0	For
Goldman Sachs	88,021	0	For
Fidelity	86,251	0	For
Lincoln Financial	55,100	0	For
Global X	43,633	0	For
AIG/SunAmerica	0	37,936	Abstain
Northern Trust	34,581	0	For
Pacific Life	32,001	0	For
Bridge Builder Trust	28,539	0	For
John Hancock	0	27,562	Abstain
SEI	18,500	0	For
Nationwide	16,930	0	For
ProShares	0	14,487	Abstain
DWS	0	11,740	Abstain
AQR	0	11,533	Abstain
Brighthouse	0	9,981	Abstain
Blackstone Alternative Investment Funds	0	9,800	Abstain
Calvert	0	7,276	Abstain
T. Rowe Price	5,369	0	For
Voya	0	5,203	Abstain
State Street	3,174	0	For
PENN SERIES FUNDS INC	2,800	0	For

Showing the 25 largest of 33 asset managers. See all 33 in the interactive database.

3. TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

98% Majority: yes · of votes cast

FOR 98%

FOR: 66,530,646AGAINST: 1,166,766

AQUESTIVE THERAPEUTICS INC.’s own tally for this item (“(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 was ratified.”): 66,530,646 for, 1,166,766 against, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,327,928 outstanding shares: 67% for, 1% against (68% of the company cast a for/against vote).

The 33 asset managers below cast 100% of the shares they voted on this item FOR (7,207,490 for, 0 against).

FOR 100%

FOR: 7,207,490 (100.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR” at AQUESTIVE THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Vanguard	3,872,326	For
BlackRock	2,404,702	For
Charles Schwab	210,669	For
Equitable	159,281	For
Goldman Sachs	88,021	For
Fidelity	86,251	For
Lincoln Financial	55,100	For
Global X	43,633	For
AIG/SunAmerica	37,936	For
Northern Trust	34,581	For
Pacific Life	32,001	For
Bridge Builder Trust	28,539	For
John Hancock	27,562	For
SEI	18,500	For
Nationwide	16,930	For
ProShares	14,487	For
DWS	11,740	For
AQR	11,533	For
Brighthouse	9,981	For
Blackstone Alternative Investment Funds	9,800	For
Calvert	7,276	For
T. Rowe Price	5,369	For
Voya	5,203	For
State Street	3,174	For
PENN SERIES FUNDS INC	2,800	For

Showing the 25 largest of 33 asset managers. See all 33 in the interactive database.

4. To elect Daniel Barber and Timothy E. Morris as Class I members of the Board of Directors, each to serve for a three-year term until the Company's 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified: Timothy E. Morris

DIRECTOR ELECTIONSOutcome not stated

— Outcome not stated · no against or withheld count reported

AQUESTIVE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Daniel Barber”): 36,060,882 for; no against or withheld count reported, per its Form 8-K filed 2025-06-11 (Item 5.07).

The 24 asset managers below cast 100% of the shares they voted on this item FOR (4,278,330 for, 0 against).

FOR 96%

FOR: 4,278,330 (95.7%)ABSTAIN: 194,485 (4.3%)

Largest asset managers voting on “To elect Daniel Barber and Timothy E. Morris as Class I members of the Board of Directors, each to serve for a” at AQUESTIVE THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,872,326	0	For
Equitable	103,991	55,290	For
Goldman Sachs	88,021	0	For
Fidelity	86,251	0	For
Lincoln Financial	55,100	0	For
AIG/SunAmerica	0	37,936	Abstain
Northern Trust	0	34,581	Abstain
Pacific Life	32,001	0	For
Nationwide	16,930	0	For
ProShares	0	14,487	Abstain
DWS	0	11,740	Abstain
AQR	0	11,533	Abstain
Brighthouse	0	9,981	Abstain
Blackstone Alternative Investment Funds	0	9,800	Abstain
Calvert	0	7,276	Abstain
T. Rowe Price	5,369	0	For
Voya	5,203	0	For
State Street	3,174	0	For
PENN SERIES FUNDS INC	2,800	0	For
Columbia Threadneedle	2,632	0	For
TIAA	2,367	0	For
Brinker Capital Destinations Trust	2,165	0	For
Victory Capital	0	1,184	Abstain
Guggenheim	0	677	Abstain

5. DIRECTOR: TIMOTHY E. MORRIS

DIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99%

The 9 asset managers below cast 100% of the shares they voted on this item FOR (2,707,113 for, 0 against).

FOR: 2,707,113 (99.0%)ABSTAIN: 27,562 (1.0%)

Largest asset managers voting on “DIRECTOR: TIMOTHY E. MORRIS” at AQUESTIVE THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
BlackRock	2,404,702	0	For
Charles Schwab	210,669	0	For
Global X	43,633	0	For
Bridge Builder Trust	28,539	0	For
John Hancock	0	27,562	Abstain
SEI	18,500	0	For
Innovator ETFs Trust	661	0	For
Advisors' Inner Circle Fund III	320	0	For
QUANTITATIVE MASTER SERIES LLC	89	0	For

Largest AQUESTIVE THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of AQUESTIVE THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 99,327,928 shares outstanding at the time of that meeting.

Top AQUESTIVE THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	BlackRock	4.61%
2	Vanguard	3.95%
3	PERCEPTIVE ADVISORS LLC	2.97%
4	Janney Montgomery Scott LLC	1.07%
5	Blue Owl Capital Holdings LP	0.93%
6	State Street	0.67%
7	Charles Schwab	0.42%
8	Woodline Partners LP	0.40%
9	Northern Trust	0.40%
10	STIFEL NICOLAUS & CO INC \MO\	0.37%

Reported AQUESTIVE THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

AQUESTIVE THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BRATTON DOUGLAS K	10.15%	13G
Douglas K. Bratton	10.15%	DEF14A
RTW Investments, LP	6.29%	13G
BlackRock	5.98%	13F
Vanguard Group	4.10%	13F
MonoLine RX II, L.P.	3.49%	DEF14A
Daniel Barber	2.68%	DEF14A
MonoLine RX III, L.P.	2.68%	DEF14A
MonoLine Partners, L.P.	1.96%	DEF14A
Geode Capital	1.71%	13F

Percentages above are of 99,327,928 shares outstanding, as reported by AQUESTIVE THERAPEUTICS INC. on its Form 10-Q dated 2025-05-08 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AQUESTIVE THERAPEUTICS INC.’s 10-Q dated 2025-05-08. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At AQUESTIVE THERAPEUTICS INC.'s shareholder meeting held 2025-06-11, in the 2024-2025 proxy season, 105 asset managers reported how they voted in their SEC Form N-PX filings, covering 469 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 83% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AQUESTIVE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-11.

AQUESTIVE THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.